Telix Pharmaceuticals Limited Unsponsored ADR earnings date
Want to see TLX full AI Analyst Report?
Telix Pharmaceuticals Limited Unsponsored ADR (TLX) Q2 2026 Earnings Report
TLX Q2 2026 EPS Results
- Actual EPS
- $0.17
- Consensus EPS
- $0.02
- Beat/Miss
- Beat by +$0.15
- One Year Ago EPS
- $0.01
TLX Q2 2026 Revenue Results
- Actual Revenue
- $478.95M
- Expected Revenue
- $247.00M
- Beat/Miss
- Beat by +$231.95M
- YoY Revenue Growth
- +22.66%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/19/2026
- Time
- After Close
- Conference Call
- Wednesday, August 19, 2026
Telix Pharmaceuticals Limited Unsponsored ADR's next earnings date is estimated for February 19, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call was strongly positive, supported by 22% group revenue growth, 146% EBITDA growth, 27% Precision Medicine growth, consecutive PSMA market-share gains, successful Gozellix adoption, a strengthened cash position and broad clinical and regulatory progress. The main negatives were Zircaix's corrected complete response letter and related manufacturing deficiencies, the uncertain Pixlumi review timeline, and the fact that the existing PSMA market is already approximately two-thirds penetrated. Overall, the highlights significantly outweigh the lowlights.
For 2026, Telix maintained full year revenue guidance of between $950 million and $970 million, expects that to land at the upper end of the range, and expects continued growth in excess of 20% year-on-year of its Precision Medicine business; full-time guidance does not reflect unapproved products, providing the potential for upside. R&D guidance was updated to a range of $230 million to $270 million. Management said Zircaix resubmission in the next month or two would be a reasonable assumption, while Pixlumi’s standardized review process is around an 18-month process and can go a little bit faster, a little bit slower depending on clock stops and review times.
- Strong First-Half Financial PerformanceH1 2026 revenue reached $477 million, up 22% compared with H1 2025. EBITDA improved 146% year-on-year to $52 million, while net profit after tax increased to $38 million. Management attributed the performance to robust commercial execution, strong demand for precision medicine products and continued control of operating expenditure.
- Precision Medicine Revenue GrowthPrecision Medicine sales were approximately $390 million, up 27% year-on-year, driven by the successful launch of Gozellix and continued growth of Illuccix. The business is tracking toward the upper end of the company's full-year revenue guidance, very close to $1 billion.
- Maintained Full-Year Revenue GuidanceTelix maintained its 2026 full-year revenue guidance of $950 million to $970 million and expects Precision Medicine revenue growth in excess of 20% year-on-year. Management expects revenue to land at the upper end of the range, and the guidance does not include unapproved products, providing potential upside.
- Improved Gross Margins and Operating DisciplinePrecision Medicine gross margin improved 1% year-on-year to 65%, driven by disciplined pricing and manufacturing and distribution efficiencies. Consolidated group gross margin improved 2% to 55%, while operating expenditure declined by 1% as a percentage of sales.
- Strong Commercial Profitability and LiquidityTelix generated $523 million of revenue and income from Precision Medicine, TMS and the Regeneron collaboration in H1 2026. Commercial profit was $153 million, representing a 29% return on revenue and income generated. Cash increased to $252 million following a refinancing of convertible bonds on better terms, giving the company financial capacity to accelerate growth.
- Continued PSMA Market-Share GainsThe PSMA business delivered $202 million of revenue in Q2, up 9% quarter-over-quarter, following $186 million in Q1, which was up 16% quarter-over-quarter. Telix increased both unit share and revenue share for the 16th consecutive quarter.
- Successful Gozellix Two-Product StrategyManagement said the Gozellix launch was successful, with strong demand from day one. The two-product strategy, combining Gozellix and Illuccix, has addressed the different needs of the company's two major customer segments and supported growth across market segments.
- International Commercial ExpansionThe PSMA portfolio has been launched or initiated across 24 countries. In China, Telix submitted its NDA and is awaiting review by the NMPA. In Japan, the company completed enrollment in its registration-enabling study with more than 100 patients and is preparing its NDA submission while awaiting feedback on conditional approval.
- Pixclara Regulatory and Commercial ReadinessTelix completed U.S. and European submissions for Pixclara, with a U.S. PDUFA date assigned for September 11. Pixclara has also been included in NCCN and international clinical guidelines. The company's commercial, medical affairs, market access and supply teams are launch ready, and an IND submission has been announced for brain metastasis, an indication with a substantially larger addressable patient population than the initial target indication.
- Progress on Zircaix Development and Regulatory ResubmissionZircaix received Breakthrough Therapy and Fast Track designations and is supported by the ZIRCON clinical data package and recognition in major international clinical guidelines. Following a corrected complete response letter from the FDA, Telix said the resubmission process is tracking against agreed timelines, with final work focused on addressing outstanding items, particularly third-party manufacturing deficiencies. Management said a resubmission in the next one to two months would be a reasonable assumption.
- BiPASS Enrollment and Potential Clinical UtilityThe BiPASS Phase III study is close to completing targeted enrollment and recruited its total sample size of approximately 350 patients in about five months. Management cited strong physician interest and said the study could support use of PSMA imaging before prostate biopsy, with the objective of halving the number of prostate biopsies while not missing patients with clinically significant prostate cancer. The study is based on prior PRIMARY and PRIMARY2 data showing improved prostate cancer detection when PSMA PET is combined with MRI.
- Therapeutic Pipeline AdvancementTelix has advanced three Phase III candidates, achieved full FDA alignment on Part 2 of the TLX591 ProstACT Global study and started dosing patients in other programs. ProstACT Global is enrolling in seven countries outside the U.S.; an additional FDA engagement is planned before filing the IND amendment for Part 2, with U.S. patient enrollment targeted for this year.
- Progress Across Early and Mid-Stage Therapeutic ProgramsEnrollment was completed in the OPTIMAL-PSMA Phase II study of TLX597, and dosing has started in the OPTIMAL-e Phase II study in metastatic hormone-sensitive prostate cancer. TLX090 is being studied in Phase I for palliation of bone pain from skeletal metastases. The Phase III IPAX BrIGHT glioblastoma study is dosing patients in its first cohort, and the LUTEON Phase III renal cell carcinoma study has activated sites and begun dosing.
- Favorable TLX597 Dosimetry DataEarly TLX597 data demonstrated a very low radiation dose to the salivary glands and kidneys while delivering a high dose to the tumor. Management described this favorable dosimetry profile as supporting development in earlier metastatic hormone-sensitive prostate cancer.
- Regeneron Collaboration and Therapeutic InnovationThe collaboration with Regeneron combines Telix's radiopharmaceutical expertise with Regeneron's biologics and antibody-engineering capabilities. The companies are focused on advancing next-generation candidates, particularly alpha therapies.
- Expanded Manufacturing and Supply-Chain InfrastructureTelix expanded manufacturing and distribution capabilities in the U.S. and Japan, opened a translational research site in Melbourne combining R&D and patient care, and continued capital expenditure at Seneffe, Yokohama and selected RLS sites. Investments include increasing clean-room capacity, installing cyclotrons and equipping and licensing RLS sites to dispense lutetium therapeutic drugs.
- RLS Revenue DiversificationTMS generated $89 million of third-party revenue, up 10% year-on-year, with a stable third-party revenue base maintained since the RLS acquisition. RLS internal revenue increased 70% year-on-year to $57 million, and RLS became Telix's second-largest distributor of its products.
- Growing R&D Investment and Pipeline FundingR&D investment represented 26% of revenue in H1 2026, focused on near-term growth opportunities and late-stage assets. Telix updated its full-year R&D guidance to $230 million to $270 million, primarily reflecting new investment across the development programs discussed and the Regeneron collaboration.
- Broad and Diversified PipelineTelix's pipeline spans urologic oncology, neuro-oncology and other tumors, including prostate and kidney cancer programs, TLX101 in glioblastoma, astatine-based alpha therapy candidates and TLX400 targeting fibroblast activation protein across a broad range of tumors. The company develops imaging agents alongside therapeutic candidates to generate biodistribution and target-selectivity data before making additional therapeutic investments.
- Therapeutic Portfolio Approach Across Prostate Cancer CareManagement described a portfolio spanning TLX591 for first- and second-line metastatic castrate-resistant prostate cancer, TLX597 for earlier metastatic hormone-sensitive disease, TLX592 as a later-line actinium-based alpha therapy and TLX090 for bone-pain palliation.
- Stable Outlook Despite TruVu Reimbursement ChangeManagement does not expect a significant impact from TruVu's reimbursement code taking effect on October 1. TruVu was described as a manufacturing improvement that would need to be rolled out across market segments, rather than a market-segmentation strategy like Telix's two-product approach. Telix has not modified its guidance.
TLX Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 19, 2027 | 2026 (Q4) | 0.06- | -0.01 | ― | ― |
| Aug 19, 2026 | 2026 (Q2) | 0.020.17 | 0.01 | 1600.00% (+0.16) | |
| Feb 19, 2026 | 2025 (Q4) | 0.04-0.01 | 0.04 | -131.58% (-0.05) | |
| Aug 20, 2025 | 2025 (Q2) | 0.180.01 | 0.06 | -83.61% (-0.05) | |
| Feb 20, 2025 | 2024 (Q4) | 0.040.04 | 0.04 | 2.70% (+0.00) | |
| Aug 22, 2024 | 2024 (Q2) | 0.100.06 | -0.03 | 310.34% (+0.09) | |
| Feb 22, 2024 | 2023 (Q4) | 0.050.04 | -0.02 | 331.25% (+0.05) | |
| Aug 23, 2023 | 2023 (Q2) | 0.04-0.03 | -0.16 | 81.88% (+0.13) | |
| Feb 27, 2023 | 2022 (Q4) | -0.05-0.02 | -0.12 | 86.67% (+0.10) | |
| Aug 17, 2022 | 2022 (Q2) | -0.08-0.16 | -0.08 | -92.77% (-0.08) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


